Last updated: December 3, 2024
Sponsor: University of Maryland, Baltimore
Overall Status: Active - Recruiting
Phase
N/A
Condition
Neuroblastoma
Cancer (Pediatric)
Retinoblastoma
Treatment
POWERbreathe Plus IMT
Clinical Study ID
NCT06205251
HP-00106329
Ages 6-12 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Completed medical treatment (chemotherapy, chemotherapy/surgery,chemotherapy/radiation or any combination of cancer treatment) for any type ofcancer, except for cancer of the central nervous system, at least 1 year ago
Exclusion
Exclusion Criteria:
History of neuromuscular, cardiac, or pulmonary disease prior to the diagnosis ofcancer
Recent injury or condition (less than 6 months ago) that precludes strength testingor walking
Dyspnea with minimal activity (4 on the modified Medical Research Council DyspneaScale)
Study Design
Total Participants: 13
Treatment Group(s): 1
Primary Treatment: POWERbreathe Plus IMT
Phase:
Study Start date:
March 15, 2024
Estimated Completion Date:
April 30, 2025
Study Description
Connect with a study center
University of Maryland, Baltimore
Baltimore, Maryland 21201
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.